Birinapant

Drug Profile

Birinapant

Alternative Names: SMAC-mimetic; TL-32711

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Princeton University
  • Developer National Cancer Institute (USA); TetraLogic Pharmaceuticals; University of Pennsylvania
  • Class Amides; Antineoplastics; Indoles; Pyrrolidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myelomonocytic leukaemia; Colorectal cancer; Myelodysplastic syndromes; Ovarian cancer
  • Phase I/II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Hepatitis B
  • Preclinical Legionella infections; Tuberculosis
  • Research HIV infections
  • No development reported Lymphoma; Pancreatic cancer

Most Recent Events

  • 29 Dec 2016 Medivir acquires birinapant from TetraLogic Pharmaceuticals
  • 02 Nov 2016 TetraLogic enters into agreement with Medivir for sale of birinapant
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma(Monotherapy) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top